2024
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson W. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer. Cancer Control 2024, 31: 10732748241250189. PMID: 38797949, PMCID: PMC11129578, DOI: 10.1177/10732748241250189.Peer-Reviewed Original ResearchConceptsMetastatic HER2+ breast cancerHER2+ breast cancerStable diseaseBreast cancerCpG-ODNTrastuzumab treatmentTreated patientsHuman epidermal growth factor receptor 2 (HER2)-positiveToll-like receptor 9 agonistHER2-positive breast cancerWeek 2Immune profile changesPeripheral blood mononuclear cellsAdvanced/Metastatic Breast CancerVEGF-D levelsOpen-label phaseNK cell populationEfficacy of current treatmentsOpen-label studyAggressive breast cancerBlood mononuclear cellsCompared to baselineMedian PFSMetastatic HER2Monocytic MDSCs
2016
Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production
Majewska-Szczepanik M, Askenase PW, Lobo FM, Marcińska K, Wen L, Szczepanik M. Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production. Journal Of Allergy And Clinical Immunology 2016, 138: 262-273.e6. PMID: 26810716, PMCID: PMC5278675, DOI: 10.1016/j.jaci.2015.11.018.Peer-Reviewed Original ResearchConceptsSubcutaneous allergen-specific immunotherapyOVA-specific IgEEpicutaneous immunizationAllergen-specific immunotherapyAntigen-specific mannerT cell receptorAllergic diseasesToll-like receptor 9 agonistMyeloid differentiation primary response 88Differentiation primary response 88Course of allergyIL-17A dependentTolerability of immunotherapyLong-term remissionTH1/TH17 cytokinesReceptor 9 agonistAdoptive cell transferEosinophil peroxidase activityEpicutaneous treatmentRegulatory cellsTh17 cytokinesAtopic dermatitisIL-10IgG2a productionIgE synthesis
2010
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 2010, 63: 975-983. PMID: 20888065, DOI: 10.1016/j.jaad.2009.12.052.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaToll-like receptor 9 agonistPF-3512676Receptor 9 agonistT-cell lymphomaSézary syndromeMycosis fungoidesIVa cutaneous T cell lymphomaRefractory cutaneous T-cell lymphomaPhase I dose-escalation studyI dose-escalation studyClass of lymphomasIndex Lesion SeverityClinical response rateCommon adverse eventsPhysician global assessmentPrimary end pointDose-escalation studyPhase I trialWeekly subcutaneous injectionsLimited therapeutic optionsTreatment of patientsEnd of studyStage IBAdverse events
2006
IL-10-deficiency unmasks unique immune system defects and reveals differential regulation of organ-specific autoimmunity in non-obese diabetic mice
Rajagopalan G, Kudva Y, Sen M, Marietta E, Murali N, Nath K, Moore J, David C. IL-10-deficiency unmasks unique immune system defects and reveals differential regulation of organ-specific autoimmunity in non-obese diabetic mice. Cytokine 2006, 34: 85-95. PMID: 16740391, DOI: 10.1016/j.cyto.2006.04.006.Peer-Reviewed Original ResearchConceptsOrgan-specific autoimmunityComplete Freund's adjuvantNOD miceRectal prolapseToll-like receptor 9 agonistSystemic inflammatory cytokine responsesTh1-type autoimmune diseaseNon-obese diabetic (NOD) micePotent anti-inflammatory cytokineCyclophosphamide-induced diabetesDiabetic NOD miceIL-10 deficiencyAnti-inflammatory cytokinesReceptor 9 agonistInflammatory cytokine responseImmune system defectsType 1 diabetesPathogen-free conditionsSplenic macrophage numbersAdoptive transferIL-10Cytokine responsesDiabetic miceFreund's adjuvantAutoimmune diseases
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply